| Name | Title | Contact Details |
|---|---|---|
Kathryn Bednarz |
Director, Clinical Laboratories | Profile |
Shari Duralek |
Director Global Clincial Supply Chain | Profile |
Steven Hagler |
Director, Technical Accounting and SEC Reporting | Profile |
Elise McCarthy |
Associate Director, Vendor Quality Assurance | Profile |
Daniel Isaacman |
Vice President Clinical Research | Profile |
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.
High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.
LUMICKS is the leading supplier of Dynamic Single-Molecule and Cell Avidity analysis instruments` Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells` Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail` Our goal is to improve human health by unlocking the power of Dynamic Single–Molecule and Cell Avidity analysis to provide unparalleled insight into the fundamental cause of disease and potential for drug optimization` These technologies are rapidly evolving as a mainstream approach in academic and pharma research for the study of DNA-protein interactions, molecular motor activity, protein folding, and cell-cell interactions`